Norway Savings Bank raised its position in Pfizer Inc. (NYSE:PFE) by 7.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,722 shares of the biopharmaceutical company’s stock after acquiring an additional 2,044 shares during the period. Norway Savings Bank’s holdings in Pfizer were worth $1,322,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. GoalVest Advisory LLC acquired a new stake in Pfizer in the second quarter valued at approximately $39,000. Lake Point Wealth Management acquired a new stake in shares of Pfizer during the second quarter worth $49,000. Harvest Fund Management Co. Ltd lifted its stake in shares of Pfizer by 25,460.0% during the second quarter. Harvest Fund Management Co. Ltd now owns 1,278 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,273 shares during the period. Activest Wealth Management acquired a new stake in shares of Pfizer during the second quarter worth $55,000. Finally, KB Financial Partners LLC acquired a new stake in shares of Pfizer during the first quarter worth $62,000. Institutional investors own 64.99% of the company’s stock.
Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. set a $42.00 price objective on shares of Pfizer in a research note on Friday, November 5th. Morgan Stanley lifted their price objective on shares of Pfizer from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 12th. Truist lifted their price objective on shares of Pfizer from $43.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday. BMO Capital Markets assumed coverage on shares of Pfizer in a research note on Thursday, November 18th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, The Goldman Sachs Group set a $48.00 target price on shares of Pfizer in a report on Thursday, July 29th. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $49.00.
NYSE:PFE opened at $50.89 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.12. The firm has a market capitalization of $285.64 billion, a price-to-earnings ratio of 15.15, a PEG ratio of 1.16 and a beta of 0.72. The company’s 50-day moving average is $45.01 and its two-hundred day moving average is $43.27. Pfizer Inc. has a 1-year low of $33.36 and a 1-year high of $52.83.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.26. Pfizer had a net margin of 27.66% and a return on equity of 31.66%. The business had revenue of $24.09 billion for the quarter, compared to the consensus estimate of $22.82 billion. During the same period in the previous year, the firm earned $0.72 EPS. The business’s revenue was up 134.4% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 4.2 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Stockholders of record on Friday, November 5th will be issued a $0.39 dividend. The ex-dividend date is Thursday, November 4th. This represents a $1.56 annualized dividend and a dividend yield of 3.07%. Pfizer’s dividend payout ratio is currently 46.43%.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.